Beneficiary Advisory Panel Handout Uniform Formulary Decisions 14 Jan 2010
|
|
- Charla Jenkins
- 5 years ago
- Views:
Transcription
1 Beneficiary Advisory Panel Handout Uniform Formulary Decisions 14 Jan 21 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review. Page 1 of 17
2 Table 1: Uniform Formulary Recommendations from the v 29 DoD P&T Committee Meeting UF Status / Brand Name (Generic) Implementation Period Phosphodiesterase Type 5 Inhibitors (PDE-5 inhibitors) for Pulmonary Arterial Hypertension Formulary Revatio (sildenafil) n-formulary Adcirca (tadalafil) recommended for NF vember 29 Recommended implementation period 6 days Figure 1: PDE5 Inhibitors for Pulmonary Arterial Hypertension 7 Utilization By Rx s ALL POS Sep 7 Sep 9 6 REVATIO 5 Rx s ADCIRCA Page 2 of 17
3 Table 2: Interferon beta 1b (Extavia): Uniform Formulary Recommendations from v 29 for the Multiple Sclerosis - Disease Modulating Drugs (MS-DMDs) Multiple Sclerosis - Disease Modulating Drugs (MS-DMDs) UF Status / Implementation Period Uniform Formulary Generic Name (Brand) Formulations Generics Available? IFN beta- 1a (Avonex) Injection IFN beta- 1a (Rebif) Injection IFN beta- 1b (Betaseron ) Injection Glatiramer acetate (Copaxone) Injection n-formulary Interferon beta 1b (Extavia) recommended for NF vember 29 Injection Recommended implementation period 6 days for Extavia Figure 2: MS-DMDs 1,2 Utilization By Rx s ALL POS Sep 7 Sep 9 COPAXONE 1, AVONEX (PREFILLED) Rx s 8 6 BETASERON 4 2 AVONEX w/albumin (VIAL) REBIF Page 3 of 17
4 Table 3: Milnacipran tablets (Savella), Bupropion hydrobromide extended release tablets (Aplenzin), and Bupropion hydrochloride extended release tablets (Wellbutrin XL): UF Recommendations from v 29 for the Antidepressant 1 (AD-1) Drugs UF Status / Implementation Period Generic Name (Brand) Antidepressant 1 (AD-1s) Formulations Generics Available? Serotonin-repinephrine Reuptake Inhibitors (SNRIs) Venlafaxine IR (Effexor) tabs Venlafaxine ER (Effexor XR) caps Venlafaxine extended release tablets (VERT) Tabs Selective Reuptake Inhibitors (SSRI) Fluoxetine (excludes Prozac Weekly, Sarafem) caps, syrup Citalopram tabs Paroxetine HCl IR tabs Paroxetine mesylate (Pexeva) tabs Sertraline (Zoloft) tabs Formulary Fluvoxamine (Luvox brand discontinued) tabs Serotonin-Antagonist/Reuptake Inhibitors (SARIs) Nefazodone tabs Trazodone tabs repinephrine and Dopamine Reuptake Inhibitors (NDRIs) Bupropion immediate release (Wellbutrin) tabs Bupropion sustained release (Wellbutrin SR) tabs Bupropion extended release (Wellbutrin XL) recommended to move from NF to UF vember 29 tabs Alpa-2 Receptor Antagonists Mirtazapine (Remeron) Tabs, n-formulary Recommended implementation period Serotonin-repinephrine Reuptake Inhibitors (SNRIs) Milnacipran (Savella ) recommended for NF vember 29 tabs Desvenlafaxine (Pristiq) tab Duloxetine (Cymbalta) caps repinephrine and Dopamine Reuptake Inhibitors (NDRIs) Bupropion hydrobromide ER tablets (Aplenzin) recommended for NF v 29 tabs Selective Reuptake Inhibitors (SSRIs) Fluoxetine weekly (Prozac Weekly) caps Fluoxetine in special packaging for premenstrual dysphoric disorder (Sarafem) caps, tabs Escitalopram (Lexapro) tabs Paroxetine ER (Paxil CR) Tabs 6 days for Savella 6 days for Aplenzin Immediate upon signing of the minutes for Bupropion XL (Wellbutrin XL, generics) Page 4 of 17
5 Figures 3 and 4: AD-1s 1,4, 1,2, Utilization - ALL POS Sep 7 Sep 9 EFFEXOR XR TOTAL QTY DISPENSED 1,, 8, 6, 4, 2, CYMBALTA LYRICA SAVELLA 6, Utilization XL S - ALL POS Sep 7 Sep 9 5, TOTAL QTY DISPENSED 4, 3, 2, 1, BUDEPRION XL WELLBUTRIN XL BUPROPION XL APLENZIN Page 5 of 17
6 Table 4: Oxybutynin 1% topical Gel (Gelnique): Uniform Formulary Recommendations from v 29 for the Overactive Bladder (OAB) Drugs Overactive Bladder Drugs UF Status / Implementation Period Generic Name (Brand) Formulations Generics Available? Darifenacin (Enablex) tabs Oxybutynin IR (Ditropan) tabs, syrup Oxybutynin ER (Ditropan XL) tabs Formulary Oxybutynin transdermal (Oxytrol) patch Solifenacin (Vesicare) tabs Tolterodine ER (Detrol LA) caps Trospium ER (Sanctura XR) caps Oxybutynin 1 % gel (Gelnique) recommended for NF vember 29 topical gel n-formulary Fesoterodine ER (Toviaz) tabs Tolterodine IR (Detrol) tabs Sanctura IR (Trospium IR) tabs Recommended implementation period ER: extended release IR: immediate release Figure 5: OABs 6 days for Gelnique Utilization - ALL POS Sep 8 Sep 9 1,8, TOTAL QTY DISPENSED 1,6, 1,4, 1,2, 1,, 8, 6, 4, OXYBUTYNIN CHLORIDE ER DETROL LA VESICARE ENABLEX 2, DITROPAN XL SANCTURA XR OXYTROL TOVIAZ GELNIQUE Page 6 of 17
7 Figure 6: OABs Con t Utilization - ALL POS Sep 8 Sep 9 7, TOTAL QTY DISPENSED 6, 5, 4, 3, 2, ENABLEX OXYBUTYNIN CHLORIDE ER VESICARE 1, DITROPAN XL SANCTURA XR OXYTROL TOVIAZ GELNIQUE Page 7 of 17
8 Table 5: Tapendatol (Nucynta) and Tramadol ER (Ryzolt): Uniform Formulary Recommendations from v 29 for the Narcotic Analgesics Narcotic Analgesics Uniform Formulary High-potency single analgesic agents Long-acting agents (> 12 hour duration) Fentanyl transdermal system (Duragesic) patch Morphine sulfate ER 24 hr (Kadian, Avinza) cap Morphine sulfate ER 12 hr (MS Contin, Oramorph) tab, soln, supp, inj Oxycodone ER (Oxycontin) tabs Oxymorphone (Opana ER) tabs Short acting agents (<12 hour duration) Codeine tabs, soln, inj Fentanyl citrate buccal (Fentora) tabs Fentanyl citrate transmucosal (Actiq) lozenges Hydromorphone (Dilaudid) tab, inj, liquid, except for 1 mg tab Levorphanol (Levo-Dromoran) tab, inj Meperidine (Demerol) tab, soln, inj Meperidine / promethazine (Mepergan Fortis) caps Methadone (Dolophine) tab, oral conc, soln, inj Morphine sulfate IR tabs Opium tincture Opium / belladonna alkaloids supp Oxycodone IR caps, oral conc, soln Oxymorphone IR (Opana) tabs High-potency combination agents Oxycodone /APAP (e.g., Percocet, Tylox, others) tab, cap, soln Oxycodone / ASA (Percodan) tabs Low potency single analgesic agents Buprenorphine (Buprenex) inj (excludes SL tabs) Butorphanol (Stadol) nasal spray, inj Pentazocine / naloxone (Talwin NX) tabs Propoxyphene (Darvon) caps, tabs Nalbuphine (Nubain ) not a controlled substance) Inj Tramadol IR(Ultram) not a controlled substance tab Low potency combination agents Codeine / APAP (Tylenol with codeine) tabs, elixir, oral susp Codeine / ASA tabs Codeine / ASA / carisoprodol (Soma) tabs Codeine / caffeine / butalbital / APAP (Fioricet with codeine) caps Codeine / caffeine / butalbital / ASA (Fiorinal with caffeine) caps, tabs Dihydrocodeine / caffeine / APAP e.g., Panlor DC, Panlor SS) caps, tabs Dihydrocodeine / caffeine / ASA (Synalgos-DC) caps Hydrocodone / APAP (Lortab, Lorcet, Vicodin) caps Page 8 of 17
9 n-formulary Recommended implementation period Pentazocine / APAP (Talacen) tabs Propoxyphene / APAP (Darvocet) tabs Propoxyphene / ASA / caffeine (Darvon Compound 65) caps Tramadol/APAP (Ultracet) not a controlled substance tab Low potency single analgesic agents Tramadol extended release (Ultram ER) tab Tramadol extended release (Ryzolt) Recommended for NF v 29 tab High potentcy single analgesic agents; short-acting agents (<12 hours duration) Tapentadol (Nucynta) Recommended for NF v 29 tab 6 days for Nucynta 6 days for Ryzolt Figure 7: Narcotics Narcotics Utilization By Rx s - ALL POS Sep 7 Sep 9 3, 2,5 MORPHINE IR RX s 2, 1,5 OXYCODONE IR 1, 5 NUCYNTA Page 9 of 17
10 Figure 8: Narcotics 7, Narcotics Utilization - All POS Sep 7 Sep 9 6, TOTAL QTY DISPENSED 5, 4, 3, 2, ULTRAM ER 1, RYZOLT Page 1 of 17
11 Table 6: Valsartan / Amlodipine / Hydrochlorothiazide (Exforge HCT) Uniform Formulary Recommendations from v 29 for the Renin Angiotensin Antihypertensives (RAAs) ARB / CCB / Diuretic Combinations ARB /CCB Combinations Direct Renin Inhibitors & Combinations ARBs ACE Inhibitors ACE/CCB Combinations Recommended implementation period Renin Angiotensin Antihypertensives (RAAs) UF n-formulary UF UF n-formulary UF NF UF n-formulary Valsartan /amlodipine / hydrochlorothiazide (Exforge HCT) recommended for UF vember 29 Olmesartan / amlodipine (Azor) Valsartan / amlodipine (Exforge) Aliskiren hydrochlorothiazide (Tekturna HCT) Aliskiren (Tekturna) Candesartan (Atacand) Candesartan /HCTZ (Atacand HCT) Losartan (Cozaar) Losartan/HCTZ (Hyzaar) Telmisartan (Micardis) Telmisartan/HCTZ (Micardis HCT) Candesartan (Atacand) Eprosartan (Teveten) Eprosartan/HCTZ (Teveten HCT) Irbesartan (Avapro) Irbesartan/HCTZ (Avalide) Olmesartan (Benicar) Olmesartan/HCTZ (Benicar HCT) Valsartan (Diovan) Valsartan/HCTZ (Diovan) Benazepril and combo with HCTZ (Lotensin, Lotensin HCT; generics) Captopril and combo with HCTZ (Capoten, Capozide; generics) Enalapril and combo with HCTZ (Vasotec, Vaseretic; generics) Fosinopril and combo with HCTZ (Monopril, Monopril HCT; generics) Lisinopril and combo with HCTZ (Prinivil, Zestril, Prinzide, Zestoretic; generics) Trandolapril (Mavik) Moexipril (Univasc) and combo with HCTZ (generics) Perindopril (Aceon) Quinapril (Accupril) and combo with HCTZ (generics) Ramipril (Altace; generics)) Amlodipine / benazepril (Lotrel; generics) Felodipine / enalapril (Lexxel) removed from market Verapamil sustained release / trandolapril (Tarka) t applicable for Exforge HCT (recommended to retain UF status) ACE: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin Receptor Blocker; CCB: Calcium Channel Blocker; HCTZ: hydrochlorothiazide Page 11 of 17
12 Figure 9: RAAS Utilization By Rx s TMOP May 7 Sep 9 2, 1,8 LISINOPRIL-HCTZ 1,6 Rx s 1,4 1,2 1, 8 6 MICARDIS HCT 4 2 TEKTURNA HCT EXFORGE HCT Page 12 of 17
13 Formulary Implementation Plan Summary 29 to present Meeting v 9 v 9 Drug Class PDE-5 Inhibitors for Pulmonary Arterial Hypertension Multiple Sclerosis- Disease Modulating Drugs (last reviewed Aug 25) n-formulary Medications Total Beneficiaries Affected (# of patients affected) Beneficiaries Affected by POS MTF Retail Mail Order Implementation Plan First Wednesday X days after the decision date tadalafil (Adcirca) days Interferon Beta-1b injection (Extavia) Aug 25: drugs made n formulary Step Therapy ; step for the class for erectile dysfunction 6 days v 9 bupropion hydrobromide extended release Aplenzin days v 9 milnacipran (Savella) days v 9 Antidepressants-1 (reviewed in v 25, Aug 8 [Pristiq]) te: Bupropion hydrochloride extended release (Wellbutrin XL, generics) recommended to move from n formulary to UF Aug 8 desvenlafaxine(pristiq) Original Meeting v 5 paroxetine HCl CR (Paxil) fluoxetine 9 mg for weekly administration (Prozac Weekly) fluoxetine in special packaging for PMDD (Sarafem) escitalopram (Lexapro) duloxetine (Cymbalta) N/A See previous BAP meetings Page 13 of 17
14 Meeting Drug Class n-formulary Medications Total Beneficiaries Affected (# of patients affected) Beneficiaries Affected by POS MTF Retail Mail Order Implementation Plan First Wednesday X days after the decision date Step Therapy v 9 Overactive Bladder Drugs (1 st reviewed Feb 6, updated Aug 8; May 9-Toviaz;) v 9 Oxybutynin 1% topical gel May 9 Fesoterodine ER (Toviaz) Update Aug 8; 1 st review Feb 6 Tolterodine IR (Detrol) Trospium IR (Sanctura) v 9 Tapentadol (Nucynta) days See previous BAP meetings days v 9 Narcotic Analgesics (1 st reviewed Feb 27) v 9 Tramadol ER (Ryzolt) days Feb 7 Tramadol ER (Ultram ER) See previous BAP meetings v 9 Renin Antihypertensive Agents (RAAs) v 9 te: Exforge HCT recommended to remain as UF N/A Page 14 of 17
15 Meeting Drug Class n-formulary Medications Total Beneficiaries Affected (# of patients affected) Beneficiaries Affected by POS MTF Retail Mail Order Implementation Plan First Wednesday X days after the decision date Step Therapy (reviewed Feb 95, May 7, v 7 [Exforge], Jun 8 [Azor] ARB/CCB combos (Jun 8) Olmesartan / amlodipine (Azor) Jun 8 Valsartan/amlodipine (Exforge) v 7 ARBs (May 7 meeting) eprosartan (Teveten) eprosartan HCTZ (Teveten HCT) irbesartan (Avapro) irbesartan HCTZ (Avalide) olmesartan (Benicar) olmesartan HCTZ (Benicar HCT) valsartan (Diovan) valsartan HCTZ (Diovan HCT) ACE/CCB combos Feb 6 meeting felodipine/enalapril (Lexxel) verapamil/trandolapril (Tarka) ACE Inhibitors (Aug 5 meeting) moexipril (Univasc), moexipril / HCTZ (Uniretic) perindopril (Aceon) quinapril (Accupril) quinapril / HCTZ (Accuretic) ramipril (Altace) See previous BAP meetings Aug 9 Phosphodiesterase Type 5 Inhibitors (PDE-5 inhibitors) for Erectile Dysfunction Aug 9; May 7 sildenafil (Viagra) tadalafil (Cialis) note: step therapy requiring trial of vardenafil (Levitra) first 14,524 (new users that will hit step) 12, days (3 Dec 29) Aug 9 Targeted Immunomodulatory Biologics (TIBs) Aug 9 certolizumab (Cimzia) golimumab (Simponi) v 7 etanercept (Enbrel) anakinra (Kineret) See previous meeting below days (3 Dec 29) Page 15 of 17
16 Meeting Drug Class n-formulary Medications Total Beneficiaries Affected (# of patients affected) Beneficiaries Affected by POS MTF Retail Mail Order Implementation Plan First Wednesday X days after the decision date Step Therapy Aug 9 Alpha-1 blocker BPH Agents Aug 9 silodosin (Rapaflo) v 7 Tamsulosin (Flomax) days (3 Dec 29) May 9 Fenofibrate acid (Trilipix) May 9 Antilipidemic II Agents (LIP-2s) Update May 7; 1 st review May 7 fenofibrate nanocrystallized (Tricor) fenofibrate micronized (Antara) omega-3 fatty acids (Omacor) colesevelam (Welchol) 4,37 4 3, days (28 Oct 9) May 9 Overactive Bladder Drugs May 9 Fesoterodine ER (Toviaz) Update Aug 8; 1 st review Feb 6 Tolterodine IR (Detrol) Trospium IR (Sanctura) days (28 Oct 9) May 9 Azelastine with Sucralose (Astepro) 6 days (28 Oct 9) May 9 Nasal Allergy Drugs Original Meeting v 8 Beclomethasone (Beconase AQ) Budesonide (Rhinocort AQ) Ciclesonide (Omnaris) Fluticasone Furoate (Veramyst) Triamcinolone (Nasacort AQ) Olopatadine (Patanase) 34, ,17 6,814 6 (8 Apr 9) May 9 PPIs May 9 Dexlansoprazole delayed release tabs (Kapidex) May 7 Update; Feb 5 1 st review lansoprazole (Prevacid) See previous meeting below 6 days (28 Oct 9) Page 16 of 17
17 Meeting Drug Class n-formulary Medications Total Beneficiaries Affected (# of patients affected) Beneficiaries Affected by POS MTF Retail Mail Order Implementation Plan First Wednesday X days after the decision date Step Therapy omeprazole/sodium bicarbonate (Zegerid) pantoprazole (Protonix) rabeprazole (Aciphex) May 9 Antiemetics May 9 Granisetron transdermal system (Sancuso) Original Meeting May 6 Dolasetron (Anzemet) days (28 Oct 9) 27 Sept 6 (6 days) Feb 9 Inhaled Corticosteroids Beclomethasone HFA MDI (Qvar) Budesonide DPI (Pulmicort Flexhaler) Ciclesonide HFA MDI (Alvesco) Flunisolide CFC MDI (Aerobid) Flunisolide CFC MDI with Menthol (Aerobid M) Triamcinolone CFC MDI (Azmacort) 13,489 3,556 7,831 2,12 12 (1 Sep 9) Feb 9 Long-Acting Beta Agonists Formoterol inhalation solution (Perforomist) (1 Sep 9) Feb 9 Inhaled Corticosteroids / Long-Acting Beta Agonist Combinations (no drugs made non-formulary) N/A N/A N/A N/A N/A N/A Page 17 of 17
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 25 March 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 25 March 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
More informationRxBlue 2010 ST Criteria
RxBlue 2010 ST Criteria ANTIDEPRESSANTS - SARAFEM... 10 FLUOXETINE HCL... 10 SARAFEM... 10 SELFEMRA... 10 ANTIDEPRESSANTS- SSRI, SNRI... 11 CELEXA... 11 CITALOPRAM... 11 CYMBALTA... 11 EFFEXOR XR... 11
More informationII. UNIFORM FORMULARY CLASS REVIEWS Phosphodiesterase Type-5 (PDE-5) INHIBITORS FOR PULMONARY ARTERIAL HYPERTENSION (PAH) P&T Comments
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationAnnual Review of Antihypertensives - Fiscal Year 2009
Annual Review of Antihypertensives - Fiscal Year 2009 Oklahoma HealthCare Authority April 2010 Current Prior Authorization Criteria There are 7 categories of antihypertensive medications currently included
More informationMedicare Shared Savings Program Accountable Care Organization (ACO) Measures Deep Dive Series
Medicare Shared Savings Program Accountable Care Organization (ACO) Measures Deep Dive Series At Risk Population: Measure 33 Coronary Artery Disease (CAD-7): Angiotensin-Converting Enzyme (ACE) Inhibitor
More informationUniform Formulary Beneficiary Advisory Panel Handout February 2006
Uniform Formulary Beneficiary Advisory Panel Handout February 2006 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinicaleffectiveness
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationADHD STIMULANTS-S(SHC)
Step Therapy Simply Health Care 2014 Formulary ID: 14406 Version: 14 Last Updated: 08/01/2014 ADHD STIMULANTS-S(SHC) Daytrana Focalin Xr Strattera Patient needs to have a paid claim for one Step 1 drug
More informationDEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS. November 2009
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS I. CONVENING II. November 2009 The Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee convened at 0800 hours
More informationGenerics. Lead with. Prescription Step Therapy Program
Lead with Generics Prescription Step Therapy Program WWW.BCBSLA.COM 04HQ3972 R11/10 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity Company GENERIC DRUGS: A
More informationLONG TERM CARE MEDICATIONS MANAGEMENT INITIATIVE JULY Prepared by the Long-Term Care Medications Management Working Group
LONG TERM CARE MEDICATIONS MANAGEMENT INITIATIVE JULY 2016 (last updated July 28, 2016) Prepared by the Long-Term Care Medications Management Working Group Drug Classes for Consideration Angiotensin Converting
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 17 September 2008
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 17 September 2008 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
More informationUF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008
UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 Promoting high quality, cost effective drug therapy throughout the Military Health System UF Decisions, May 07 Class FY05 rank, total $
More informationGenerics. Lead with. P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m
Lead with Generics P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m WWW.BCBSLA.COM 04HQ3972 5/09 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity
More informationHave You Ever Wondered
Have You Ever Wondered A few facts about medication use and related falls The Number of Medications You Take & The Connection to Falls CONCERN: As you increase the number of medications that you take,
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 8 January 2008
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 8 January 2008 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 08 Jan 2009
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 08 Jan 2009 PURE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
More informationTRICARE Uniform Formulary. Pre-Authorization Requirements
TRICARE Uniform Formulary Pre-Authorization Requirements The Department of Defense (DoD) requires pre-authorization on select medications. These medications are on the DoD s pre-authorization list because
More informationUniform Formulary Beneficiary Advisory Panel Handout September 2005
Uniform Formulary Beneficiary Advisory Panel Handout September 2005 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical-effectiveness
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 6 Jan 2011
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 6 Jan 2011 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
More information4/3/2014 OBJECTIVES BLOOD PRESSURE BASICS. Discuss the new blood pressure guidelines (JNC 8) and recognize the changes from JNC 7
1 OBJECTIVES Discuss the new blood pressure guidelines (JNC 8) and recognize the changes from JNC 7 Review mechanisms for the main drug classes used to treat hypertension Describe the dosing strategies
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationResponsible Quantity Program Effective 4/1/10. Abilify oral solution
Abilify Abilify Discmelt Abilify oral solution Aciphex Actiq Page 1 of 9 750 ml 120 units Actonel 5 mg, 30 mg Actonel 35 mg 4 tabs Actonel 75 mg 2 tabs Actonel 150 mg 1 tab Actonel with Calcium Adcirca
More informationXyrem (Sodium Oxybate)
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationOpiate/Benzodiazepine/Muscle Relaxant Combinations
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Opiate/Benzodiazepine/Muscle Relaxant Combinations Clinical Edit Information Included in this Document Drugs requiring prior authorization:
More informationPlan Year CCHP Senior Program (HMO) Step Therapy Criteria (ST)
Plan Year 2016 CCHP Senior Program (HMO) Step Therapy Criteria (ST) Step Therapy: In some cases, CCHP Senior Program (HMO) requires you to first try certain drugs to treat your medical condition before
More informationInstructions and Checklist for Your Heart Procedure
PATIENT EDUCATION Instructions and Checklist for Your Heart Procedure allinahealth.org 2016 ALLINA HEALTH SYSTEM. TM A TRADEMARK OF ALLINA HEALTH SYSTEM. OTHER TRADEMARKS USED ARE OWNED BY THEIR RESPECTIVE
More informationStep Therapy Medications
Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on
More informationClinical Teach-Back Cards
Clinical Teach-Back Cards The Medicare Quality Improvement Organization for Texas TMF Health Quality Institute focuses on improving lives by improving the quality of health care through contracts with
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Controlled Substance Analgesic and Narcotic Antagonist Quantity Limitations Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing
More information12.5mg, 25mg, 50mg. 25mg, 50mg. 250mg, 500mg, 250mg/5ml. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 9/11/2018 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 5/17, 9/15, 2/13, 2/08, LOB
More information2013 Step Therapy (ST) Criteria
2013 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other BUPROPION HCL WELLBUTRIN, 01653 WELLBUTRIN SR, WELLBUTRIN XL BUPROPION HBR APLENZIN 17050 16996 26198 CITALOPRAM CELEXA 10321 GPID 16344 HYDROBROMIDE DESVENLAFAXINE
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 24 July 2008
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 July 2008 PURE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
More informationDrugs That Have Quantitiy Limits (QL)
Drugs That Have Quantitiy Limits (QL) There are Quantity Limits set by your UA Medicare Group Part D Prescription Drug Plan for the drugs listed below. The UA Medicare Group Part D Prescription Drug Plan
More informationMorphine IR Hydromorphone IR Oxymorphone IR. Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone),
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.33 Subject: Morphine IR Drug Class Page: 1 of 11 Last Review Date: December 8, 2017 Morphine IR Hydromorphone
More information12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER)
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 9/15, 2/13, 2/08, 5/07 LOB
More informationCerner Bulletin Providers Issued: October 2, 2014
Alert Warfarin Ordered without INR CPOE, Nursing and Pharmacy 10/13/14 S B A R Prescribers currently do NOT get a warning if warfarin is actively ordered and there has not been an INR result in the past
More informationCNS DEPRESSANT OVERDOSE
Signs and symptoms of CNS depressant overdose include: altered mental status, respiratory depression, hypotension, bradycardia, pulmonary edema, coma, and constricted pupils (opioids only). The following
More informationSTEP THERAPY ALGORITHMS PUP Select Formulary
The Step Therapy drug will be dispensed if the drug has been dispensed within 120 days of current fill or if alternative (Step 1) drugs have been used first. If the member s prescription claim fails the
More informationACE Inhibitors and ARBs To Protect Your Heart? A Guide for Patients Being Treated for Stable Coronary Heart Disease
ACE Inhibitors and ARBs To Protect Your Heart? A Guide for Patients Being Treated for Stable Coronary Heart Disease Is This Guide Right for Me? This Guide Is for You If: You have coronary heart disease,
More informationPerformance Drug List Change Detail Report Effective (Standard Drug List Reflects Exclusions)
This report highlights all changes (additions and deletions) to the CVS Caremark Performance Drug List. ADDITIONS: Brand Agents: Betaseron (interferon beta-1b) Central Nervous System/ Multiple Sclerosis
More informationClinical Policy: Angiotesin II Receptor Blockers and Renin Inhibitors Reference Number: CP.HNMC.15 Effective Date: Last Review Date: 08.
Clinical Policy: Reference Number: CP.HNMC.15 Effective Date: 11.16.16 Last Review Date: 08.17 Revision Log Line of Business: Medicaid Medi-Cal See Important Reminder at the end of this policy for important
More informationClinical Teach-Back Cards
Clinical Teach-Back Cards The Quality Innovation Network - Quality Improvement Organization (QIN-QIO) for Delaware, Louisiana, New Jersey, Pennsylvania and West Virginia The people at Quality Insights
More informationSouth Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call To Order A meeting of the
More informationCapital BlueCross Open/Closed Formulary Update (1 st Quarter 2017)
Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017) The Capital BlueCross formulary is a reference list of prescription drugs that contains a wide range of generic and brand drugs that have
More informationOpioid Analgesic/Opioid Combination Products
Market DC Opioid Analgesic/Opioid Combination Products Override(s) Quantity Limit Approval Duration 1 year Generic Name Brand Name Quantity Limit APAP/Caf/Dihydrocodeine 320.5mg/30mg/16mg APAP/Caf/Dihydrocodeine
More informationClinical Policy: ACEI and ARB Duplicate Therapy Reference Number: CP.PMN.61 Effective Date: Last Review Date: 05.18
Clinical Policy: Reference Number: CP.PMN.61 Effective Date: 08.01.14 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationAPPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION
Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION PROVIDER GROUP Pharmacy Opioid Products Indicated for Pain Management MANUAL GUIDELINES All dosage forms
More informationASEBP and ARTA TARP Drugs and Reference Price by Categories
ASEBP Pantoprazole Sodium 40 mg (generic) $0.2016 ASEBP Dexlansoprazole 30 mg Dexlansoprazole 60 mg Esomeprazole 10 mg Esomeprazole 20 mg Esomeprazole 40 mg Lansoprazole 15 mg Lansoprazole 30 mg Omeprazole
More informationStep Therapy Medications
Step Therapy Medications Step Therapy Group APTIOM Step-2: APTIOM 200 MG TABLET or APTIOM 400 MG TABLET or APTIOM 600 MG TABLET or APTIOM 800 MG TABLET Step 1 Drug(s): Oxcarbazepine immediate-release,
More informationANTICHOLINERGIC BRONCHODILATORS ANTICHOLINERGIC BETA-AGONIST COMBO'S CORTICOSTEROID / BRONCHODILATOR COMBO'S NASAL STEROIDS LEUKOTRIENE MODIFIERS
1 of 5 ALLERGY / ASTHMA THERAPIES ANTIHISTAMINES, MINIMALLY SEDATING cetirizine fexofenadine loratadine ANTIHISTAMINE/DECONGESTANT COMBINATIONS cetirizine/pseudoephedrine fexofenadine/pseudoephedrine loratadine/pseudoephedrine
More informationLisinopril 20 converting to losartan
Search Lisinopril 20 converting to losartan Stop wasting your time with unanswered searches. lisinopril 40 mg to losartan conversion,cannot Find low price Best. Winds SSW at 10 to 20. Lisinopril 20 to
More informationPDF created with pdffactory trial version
We are using more prescription drugs than ever before to manage health conditions and prevent problems. And those drugs are more expensive than ever before. In 2003, prescription drug costs in the United
More information2015 Chinese Community Health Plan Senior Program (HMO) Step Therapy Criteria Last Updated 11/1/2015
2015 Chinese Community Health Plan Senior Program (HMO) Step Therapy Last Updated 11/1/2015 APLENZIN TAB 174MG, 348MG, 522MG Step Therapy requires trial of bupropion SR or bupropion XL in previous 180
More informationSummary ofpanel Vote/Comments:
14 August 2009 Executive Summary UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL COMMENTS 30 July 2009 The Unifonn Fonnulary (UF) Beneficiary Advisory Panel (BAP) commented on the recommendations from the
More informationValue-Based Drug List for ABCs of Diabetes
Effective January 1, 2019 Value-Based Drug List for ABCs of Diabetes PCPS provides a Value-Based Benefit Design (VBD) to qualified participants in the ABCs of Diabetes. This means you will have lower out-of-pocket
More information90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR
Pre - PA Allowance 12 years of age or older Quantity Immediate-release Formulation Ultracet 720 dosage units per 90 days OR Ultram 720 dosage units per 90 days Extended-release Formulations Ultram ER 90
More informationII. UF CLASS REVIEWS NASAL ALLERGY DRUGS
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationMORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone)
Pre - PA Allowance Tablets & Suppositories Morphine sulfate tablets Morphine sulfate suppositories Oxymorphone tablets Hydromorphone tablets Hydromorphone suppositories 360 tablets per 90 days OR 360 suppositories
More informationNew Hampshire Healthy Families CLINICAL POLICY
New Hampshire Healthy Families CLINICAL POLICY DEPARTMENT: Pharmacy DOCUMENT NAME: Opioid Analgesics PAGE: 1 o f 6 REFERENCE NUMBER: NH.PPA.13 EFFECTIVE DATE: 6/1/2016 REPLACES DOCUMENT: N/A RETIRED: REVIEWED:
More informationAnthem Prescription Management s Clinical Connections Program
Anthem Prescription Management s Clinical Connections Program Anthem Prescription is committed to helping you manage your health care benefits. Prior Authorization, Quantity Limits and are edits recommended
More informationII. Angiotensin Receptor Blockers (ARBs) Drug Class Review
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE DOD BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32 C.F.R. 199.21,
More informationDrug Regimen Optimization
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description
More informationDrug Regimen Optimization
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description
More informationOpioid Analgesic/Opioid Combination Products
Opioid Analgesic/Opioid Combination Products Override(s) Quantity Limit Approval Duration 1 year Generic Name Brand Name Quantity Limit 320.5mg/30mg/16mg 356.4mg/30mg/16mg 325mg/30mg/16mg Trezix (new formulation)
More informationAmlodipine/olmesartan (Azor ) is indicated for the treatment of hypertension, alone or in combination with other antihypertensive medications.
Page 1 of 8 Policies Repository Policy Title Policy Number Oral Antihypertensive Agents FS.CLIN.9 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product
More informationLevorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 16, 2018 Levorphanol Description Levorphanol
More informationHYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.
Pre - PA Allowance None Prior authorization is not required if prescribed by an oncologist. Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: 1. Pain,
More informationCHAMP: Bedside Teaching TREATING PAIN. Stacie Levine MD. What is the approach to treating pain in the aging adult patient?
CHAMP: Bedside Teaching TREATING PAIN Stacie Levine MD Teaching Trigger: An older adult patient is identified as having pain. Clinical Question: What is the approach to treating pain in the aging adult
More informationPre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None
Pre - PA Allowance None Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist and/or the member has paid pharmacy claims for an oncology medication(s) in the past
More information2014 Quantity Limits (QL) Criteria
2014 Quantity Limits (QL) Criteria Certain drugs covered through your EmblemHealth Medicare HMO/PPO Medicare Plan are covered for only a limited quantity. We do this to ensure compliance with the US Food
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 2011
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 211 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
More informationSTEP THERAPY. Cigna Pharmacy Management. What is Step Therapy?
STEP THERAPY Cigna Pharmacy Management What is Step Therapy? Prescription medications cost a lot of money. At Cigna, we get that. That s why we ve created a program that helps save you money and stay healthy.
More informationFirstCarolinaCare Insurance Company Step Therapy Requirements
ANALGESICS, NARCOTICS KADIAN MORPHINE SULFATE ER PRIOR CLAIM FOR MORPHINE SULFATE SUSTAINED ACTION TABLET (MS CONTIN) WITHIN THE PAST 120 DAYS. ANTIBACTERIALS (EENT) BESIVANCE PRIOR CLAIM FOR CIPROFLOXACIN
More informationARBS MEDICATION(S) SUBJECT TO STEP THERAPY DIOVAN HCT MG TAB, DIOVAN HCT MG TABLET
ARBS DIOVAN HCT 160-12.5 MG TAB, DIOVAN HCT 80-12.5 MG TABLET 30-day trial of a Step 1 drug in the previous 120 days is required. Step 1 Drugs: Losartan, Losartan/HCTZ PAGE 1 LAST UPDATED 05/2016 BILE
More informationConnecticut Medicaid P&T Meeting Minutes June 5, 2008
Connecticut Medicaid P&T Meeting Minutes June 5, 2008 The meeting started at 6:30 pm Attendance Present Members: Carl Sherter, MD Kenneth Marcus, MD Lester Silberman, MD Peggy Manning Memoli, Pharm D Richard
More informationSTATE OF NEW YORK DEPARTMENT OF HEALTH
STATE OF NEW YORK DEPARTMENT OF HEALTH Corning Tower The Governor Nelson A. Rockefeller Empire State Plaza Albany, New York 12237 Antonia C. Novello, M.D., M.P.H., Dr.P.H. Commissioner Dennis P. Whalen
More informationNucynta IR. Nucynta IR (tapentadol immediate-release) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta IR Page: 1 of 9 Last Review Date: December 8, 2017 Nucynta IR Description Nucynta IR (tapentadol
More informationOXYCODONE IR (oxycodone)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Oxycodone hydrochloride, a pure opioid agonist, is used in the treatment of moderate to severe pain (1-2). The precise mechanism of action is unknown; however,
More informationSTATE OF NEW YORK DEPARTMENT OF HEALTH
STATE OF NEW YORK DEPARTMENT OF HEALTH Corning Tower The Governor Nelson A. Rockefeller Empire State Plaza Albany, New York 12237 Antonia C. Novello, M.D., M.P.H., Dr.P.H. Commissioner Dennis P. Whalen
More informationLevorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 17, 2017 Levorphanol Description Levorphanol
More informationAvoid paying too much for your prescriptions
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions 2017 Aetna Rx Step Program Medicine List Avoid paying too much for your prescriptions It s important to try to
More information5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release
5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum.
More information5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release
5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum.
More information5-ASA. Products Affected DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED RELEASE. Details
5-ASA DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum. 1 ANTIEMETICS
More information5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release
Updated 11/1/17 5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda
More informationCardiac Medications At A Glance
Cardiac Medications At A Glance 1) Anticoagulants (Also known as Blood Thinners.) Dalteparin (Fragmin), Danaparoid (Orgaran) Enoxaparin (Lovenox) Heparin (various) Tinzaparin (Innohep) Warfarin (Coumadin)
More informationOpioid Management Program May 2018
Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily
More informationANTIDEPRESSANTS - BUPROPION
Step Therapy Paramount Medicare Formulary 2012 Formulary ID 12112, Version 22. CMS Approved 10-23-2012. ANTIDEPRESSANTS - BUPROPION Aplenzin may be given. Step 1 Drug(s): Budeprion Sr, Budeprion Xl, Bupropion
More informationOpioid Management Program October 2018
Opioid Management Program October 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of
More information2018 Step Therapy Criteria
2018 Step Therapy Criteria ANGIOTENSIN RECEPTOR BLOCKERS... 2 ANTIDEPRESSANTS... 3 ANTIDEPRESSANTS, MISCELLANEOUS... 4 ANTIDEPRESSANTS, OTHER... 5 ANTIDIABETIC AGENTS... 6 ANTIGOUT AGENTS... 7 ANTIHYPERTENSIVE
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Step Therapy Individual and Family Plan Table of Contents Coverage Policy... 1 General Background... 5 References... 5 Effective Date... 3/15/2018 Next Review
More informationPrescription benefit updates Large group
Prescription benefit updates Large group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe effective medication treatments. The program also helps you save money
More informationPRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select October 1, 2018 Updates Drug Name efavirenz 600mg (Brand = Sustiva ) trientine (Brand = Syprine ) hydrocortisone lot 0.1% (Brand = Locoid ) sumatriptan-naproxen
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 24 Sept 2009
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 Sept 2009 PURE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
More informationConversion of losartan to lisinopril
Cari untuk: Cari Cari Conversion of losartan to lisinopril Dania Alsammarae, Strategy Director and co-founder of Anglo Arabian Healthcare speaks with Neil Halligan of Arabian Business on what it takes
More information